The role of the third variable domain (V3) of gp120 in the neutralization of primary and T-cell line adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1) by serum from HIV-1-infected individuals was investigated. A primary virus isolate, M2424/4, when adapted to H9 cells, was more sensitive to neutralization on MT2 cells than the same stock passaged in PBMC. Neutralization of the PBMC-passaged stock by V3-specific MAbs was abrogated by addition of V3 (MN) peptide. However, exogenous V3 (MN) peptide failed to reduce the neutralization of this isolate on PBMC, or MT2 cells, by high titre anti-HIV-1 polyclonal human sera in contrast to the extensive reduction of neutralization by the same sera on MT2 cells using the prototype MN strain (4-to 24-fold) and the TCLA M2424/H9 isolate (2-to 8-fold). These results indicate that the neutralization of primary virus isolates by serum from HIV-1-infected individuals is not significantly mediated by V3-specific antibodies.
The role of the third variable domain (V3) of gp120 in the neutralization of primary and T-cell line adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1) by serum from HIV-1-infected individuals was investigated. A primary virus isolate, M2424/4, when adapted to H9 cells, was more sensitive to neutralization on MT2 cells than the same stock passaged in PBMC. Neutralization of the PBMC-passaged stock by V3-specific MAbs was abrogated by addition of V3 (MN) peptide. However, exogenous V3 (MN) peptide failed to reduce the neutralization of this isolate on PBMC, or MT2 cells, by high titre anti-HIV-1 polyclonal human sera in contrast to the extensive reduction of neutralization by the same sera on MT2 cells using the prototype MN strain (4-to 24-fold) and the TCLA M2424/H9 isolate (2-to 8-fold). These results indicate that the neutralization of primary virus isolates by serum from HIV-1-infected individuals is not significantly mediated by V3-specific antibodies.
It is likely that an effective vaccine against human immunodeficiency virus type 1 (HIV-1) infection will need to induce, in addition to other effectors of immunity, antibodies capable of neutralizing the infectivity of field isolates in vivo. To date, several groups have demonstrated that, in contrast to sera from HIV-1-infected individuals, immune sera from human vaccinees immunized with diverse monomeric env constructs do not possess antibodies capable of neutralizing primary field Author for correspondence : Jonathan N. Weber.
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isolates in vitro, when using activated PBMC as cellular targets (Cohen, 1993 ; Mascola et al., 1996) , suggesting that there are qualitative differences between patients ' serum and serum generated to monomeric vaccines (VanCott et al., 1995 a) . Concurrently, it has been reported that the relative resistance of primary isolates to neutralization by diverse reagents is due in part to the host cell in which the virus stock is propagated (Sawyer et al., 1994 ; Wrin et al., 1995) . The V3 loop is an important neutralizing determinant of T-cell line adapted (TCLA) strains (Javaherian et al., 1989) , but its significance in the neutralization of primary strains is unclear (Bou Habib et al., 1994) .
Here we confirm that adaptation of a primary virus to H9 cells results in an increased sensitivity to neutralization by human anti-HIV-1 polyclonal sera, and demonstrate that this increased neutralization-sensitivity is due in part to V3-specific antibodies. Furthermore, whilst neutralization of primary isolates in PBMC by V3-specific antibodies is achievable, it is unlikely that V3 antibodies in sera from HIV-1-infected individuals contribute significantly to the neutralization of these isolates. Thus, if a vaccine is to induce group-specific neutralizing antibodies for field isolates of HIV-1, regions other than the V3 domain are likely to be important.
The role of the V3 domain in the neutralization of primary and TCLA isolates of HIV-1 was examined in a series of peptide-inhibition assays. The sera used were obtained with informed consent from HIV-1-infected individuals resident in the UK (apart from FDAF2 which was of North American origin) and heat inactivated (56 mC for 35 min) prior to use. Neutralization of the HIV-1 MN strain by serum from a HIV-1-infected individual (049) and a V3-specific MAb (257-D), and inhibition of this neutralization in a dose-dependent manner by exogenously added MN V3 peptide, but not the heterologous HXB2 peptide, is shown in Fig. 1 (a, b) , respectively. Endpoint neutralization titres were determined on C8166 cells as described previously (Cheingsong-Popov et al., 1992 ; 50 µl), followed after 1 h at 37 mC by 5i10% C8166 cells. The reciprocal of the final dilution of serum or MAb which reduced the formation of syncytium by 90 % (RNT *! % ) was determined for each peptide concentration. This reduction in V3-specific neutralization was found to a greater or lesser extent with all sera tested (data not shown), confirming the observation of others that the V3 loop contains important immunodominant epitopes (Javaherian et al., 1989) , and that a substantial proportion of the HIV-1 MN neutralizing antibodies found in serum from HIV-1-infected individuals are directed to this region (Zwart et al., 1994) .
To determine if this region is as important in the context of primary virus neutralization we undertook similar peptideinhibition assays using a syncytium-inducing primary isolate, M2424\4, passaged both in PBMC and following multiple passage in H9 cells. This genetic subtype B virus was isolated from a London AIDS patient by co-culture with 3-4 day phytohaemagglutinin (PHA)-stimulated seronegative PBMC (National Blood Service North London, UK) in RPMI 1640 medium supplemented with 15 % FCS, antibiotics and, post PHA-stimulation, 10 IU\ml recombinant interleukin-2 (MRC ARP). For clarification the PBMC-grown stock is designated M2424\PBMC and the TCLA stock, M2424\H9.
The acquired neutralization sensitivity following passage of primary virus stock in H9 cells (Sawyer et al., 1994 ; Wrin et al., 1995) was confirmed, by blinded comparison of RNT *! % values using a panel of 23 HIV-1-positive sera, of both HI HIV-1 V3-specific antibody neutralization HIV-1 V3-specific antibody neutralization M2424\PBMC and M2424\H9 virus stocks, on MT2 cells. Briefly, 50 µl of diluted serum was incubated with 50 TCID &! of virus for 1 h at 37 mC after which time 2n5i10% MT2 cells were added. By comparison of the RNT *! % for each serum, the neutralization of the M2424\PBMC virus was 4-fold less susceptible to neutralization than its TCLA counterpart, M2424\H9 (n l 23, P l 0n0014 ; Wilcoxon signed rank test).
We examined the role of the V3 domain in the neutralization of M2424\PBMC, using an infectivity reduction assay format (Fig. 1 c) . Briefly, 75 µl of serum (1 : 20 dilution), or serum pre-incubated with 100 µg\ml MN V3 peptide, was added to quadruplicate wells of 5-fold virus dilutions followed, after 1 h incubation at 37 mC, by addition of 10& PHAstimulated PBMC. Cultures were washed on days 1, 2 and 3 and p24 antigen determinations (Moore, 1992) were performed on day 7 supernatants when wells were scored positive or negative according to the assay cutoff (twice the meanj3 SD of virus alone wells). The virus inoculum p24 antigen is reduced to below detectable levels and the residual p24 antibody is diluted to approximately 5i10 −% by this wash procedure. The endpoint virus dilution producing 50 % infected cultures (TCID &! ) was determined using a PC program based on the Karber equation Fig. 1 (c) . Whilst the neutralization by the anti-V3 MAbs was abrogated by addition of MN V3 peptide, the human sera were not significantly affected (n l 10, P l 0n8203). This is in contrast to a significant reduction in the RNT *! % of the MN (median 5-fold reduction, n l 10, P l 0n0020) and M2424\H9 (3-fold, n l 10, P l 0n0078) strains by the same sera, performed using the C8166-based assay described above (data not shown).
To overcome potential differences between the C8166 and PBMC formats, peptide-inhibition assays were performed on MT2 cells, described above, with both M2424\4 virus stocks and the MN strain. For comparison of data, the V3 peptideinhibition index is presented as a ratio of the RNT *! % obtained in the absence of peptide over the RNT *! % obtained in the presence of excess (25 µg\ml) MN V3 peptide (Fig. 1 d) . The RNT *! % of HIV-1-positive serum was reduced, 4 to 24-fold for the MN strain, 2 to 8-fold for the M2424\H9 strain and, apart from the case of serum 089, not at all for the M2424\PBMC isolate.
Core antigen (p24) measurements were performed on supernatants from a similar experiment to that shown in Fig.  1(d) , except that stringent washing was done to remove input virus and p24 antibodies, confirming the sensitivity of the MN and M2424\H9 viruses, but not the M2424\PBMC virus, to V3-mediated neutralization by a representative human serum (049) (Fig. 2 ). The 50 % neutralization level in the absence or presence of V3 peptide revealed that while the neutralization of the MN strain was markedly inhibited by excess V3 peptide and the M2424\H9 strain less so, the neutralization of the M2424\PBMC isolate was unaffected. This suggests that the remainder of antibodies in HIV-1-positive human serum, once V3 antibodies have been competed out, were responsible for the neutralization of this primary isolate.
Taken together, these data demonstrate that while the level of V3 peptide-inhibition of neutralization varied between sera, neutralization of the M2424\PBMC virus by HIV-1-positive sera was not mediated by V3 loop antibodies in contrast to its HJ S. Beddows and others S. Beddows and others TCLA counterpart. Similar work (VanCott et al., 1995 b) , using V3 peptide-depleted sera, demonstrated that while the role of the V3 domain in primary isolate neutralization using human serum cannot be discounted, there are ' distinct and potentially important differences in V3 epitope-specific antibody function in mediating neutralization ' between TCLA and primary strains of HIV-1.
Single molecules of HIV-1 provirus were isolated by limiting dilution and amplified in a nested PCR to produce sufficient DNA to allow direct sequencing of the PCR products according to published protocols [Hughes et al., 1997 (V1\V2) and Donaldson et al., 1994 (V3) ]. Amino acid sequences of the V3 loops of the M2424\PBMC and M2424\H9 viruses were identical (Fig. 3) . Significantly, there is an H A substitution at position 13 of the V3 loop providing an explanation for the poor reactivity of the 257-D (KRIHI epitope) and 268-D (HIGPGR ; MRC ARP, UK) MAbs against the M2424\4 viruses, and for the effective neutralization of these strains by the anti-V3 cocktail, containing the broadly reactive 447-52D MAb (Conley et al., 1994) . There were several amino acid differences within the V1 and V2 domains between the M2424\PBMC and M2424\H9 viruses, suggesting a heterogeneous population in the uncloned viral stock rather than multiple substitutions during passage, which may have accounted for some of the non-V3-dependent neutralization sensitivities of these two viruses. Amino acid changes in the V1 and V2 domains have been implicated by some (Boyd et al., 1993 ; Groenink et al., 1993) but not others (Wang et al., 1995) in the determination of cellular tropism and it is possible that the observed differences could result in secondary structure rearrangements, and\or differential gp160 glycosylation, between the PBMC and TCLA strains, thus modulating exposure of the V3 loop to antibody-dependent neutralization.
Whilst the use of a single clade B MN peptide may limit interpretation of the inhibition data, and exclude the potential effect of non ' MN like ' V3 antibodies, one report demonstrated (VanCott et al., 1995 b) that the linear MN V3 peptide depleted HIV-1-positive human serum of 99 % of V3 antibodies, suggesting that the precise epitope matching of peptides may not be essential in such studies.
The differential sensitivity of the PBMC and TCLA strains to V3-specific antibody neutralization in MT2 cells suggests this is a cell-acquired, virus-dependent phenomenon. The apparent cryptic nature of the V3 loop on virion-associated gp120 was highlighted using a CD4 + T-cell line chronically infected with macrophage-tropic and T-cell line tropic variants of JR-CSF (Bou Habib et al., 1994) . Several studies subsequently demonstrated a reduced capacity of V3-specific MAbs to bind to the oligomeric form of HIV-1 gp120 and that this antibody reactivity, in contrast to monomeric gp120 binding, correlated with the neutralization of primary HIV-1 isolates Sullivan et al., 1995 ; Fouts et al., 1997) . The increased neutralization sensitivity associated with adaptation of primary virus to H9 cells (Sawyer et al., 1994 ; Wrin et al., 1995) is likely to be due to subtle changes in the oligomeric arrangement of the envelope glycoprotein on the virion surface , especially in this case where the V3 sequences of the PBMC and TCLA viruses were identical. Strong supportive evidence that the V3 domain is not a major factor in determining the neutralization of primary HIV-1 isolates has been demonstrated by checkerboard studies using serum and field isolates from multiple genetic subtypes (Moore et al., HIV-1 V3-specific antibody neutralization HIV-1 V3-specific antibody neutralization 1996 ; Weber et al., 1996) . It is possible that, post gp120-CD4 binding, antibodies to the V3 domain, acting alone or in concert with other antibodies, prevent binding to the HIV-1 co-receptors CXCR-4 and\or CCR-5 (Wu et al., 1996 ; Trkola et al., 1996) and ultimately block HIV-1 entry. While the data presented in this report do not preclude such a role for the V3-specific antibodies found in serum from HIV-1-infected individuals, it is clear that the V3 domain is not as significant a neutralization determinant in the context of primary isolate neutralization as it is for TCLA strains.
